Quantcast

Latest Transition Therapeutics Inc. Stories

2014-07-11 08:24:07

TORONTO, July 11, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) Chairman and Chief Executive Officer, Dr. Tony Cruz is pleased to announce that Carl Damiani has been appointed to the role of Chief Operating Officer of Transition. "This appointment reflects Mr. Damiani's broader leadership role in overseeing Transition employees and operations in Toronto, San Francisco and Ireland, as well as advancing our late stage...

2014-06-23 08:27:24

TORONTO, June 23, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) announced that it has closed its previously announced private placement through which 3,195,487 units of the Company were purchased by Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders. Gross proceeds of the private placement totalled US$17 million. As previously...

2014-06-06 08:25:27

Company to Receive Upfront US$17 Million Upon Closing TORONTO, June 6, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders will make an investment of up to US$30.8 million by purchasing 3,195,487 units of the Company at a price of US$5.32 per unit. Each unit consists...

2014-05-27 08:29:06

Live Webcast Beginning at 8am Eastern Time on May 28th TORONTO, May 27, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) announced today that it will host an Investor Day on Wednesday, May 28th in New York City. An industry key opinion leader, Constantine G. Lyketsos, MD, and Transition's executive management team will offer insights into Transition's lead drug candidate, ELND005, and its potential role in the treatment...

2014-05-15 08:31:10

TORONTO, May 15, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient in a Phase 2 clinical study of TT-401 (LY2944876), a drug candidate for the treatment of type 2 diabetes. The study is expected to enroll up to 375 type 2 diabetes subjects and will be performed by Transition's development partner, Eli Lilly and Company ("Lilly"). The objectives of the study will be to...

2014-05-13 16:28:39

TORONTO, May 13, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three and nine month periods ended March 31, 2014. Selected Highlights Highlights for the Company during the nine month period ended March 31, 2014 and up to the date of this MD&A include the...

2014-05-12 08:30:41

TORONTO, May 12, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Tuesday, May 13th, 2014 at 4:30 P.M. EST to discuss Third Quarter Fiscal 2014 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the...

2014-04-07 08:29:21

TORONTO, April 7, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) provided an update on the development of its drug candidates and plans for future growth. The addition of the neuropsychiatric drug candidate ELND005 has broadened the Company's development pipeline with an un-partnered late-stage clinical asset, coupled with Transition's core strategy of advancing assets acquired from pharmaceutical partners. From a...

2014-03-03 12:26:58

TORONTO, March 3, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the 34(th) Annual Cowen & Co. Healthcare Conference on Tuesday, March 4th, 2014 at 10:00 a.m. Eastern Time at the Boston Marriott Copley Place Hotel in Boston, MA. About Transition Transition is a biopharmaceutical company, developing novel...

2014-02-28 08:25:07

-- All development and commercialization rights of ELND005 drug candidate have been transferred to an Irish-domiciled company ("Irish Subsidiary") -- Transition has acquired 100% of the common shares of Irish Subsidiary -- Irish Subsidiary will be responsible for the future development and commercialization of ELND005 for all disease indications -- Affiliates of Perrigo Company plc ("Perrigo") will...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related